Compliance Monitoring Report Technical Assistance Tool, 2008

This form requests the minimum information required to demonstrate the extent of compliance with section 223(a)(11), 223(a)(12), 223(a)(13), 223(a)(14) of the JJDP Act of 2002. Many of these reporting requirements may be found in 28 C.F.R. 31.303(f)(5).

Compliance Monitoring Report Technical Assistance Tool, 2009

This form requests the minimum information required to demonstrate the extent of compliance with section 223(a)(11), 223(a)(12), 223(a)(13), 223(a)(14) of the JJDP Act of 2002. Many of these reporting requirements may be found in 28 C.F.R. 31.303(f)(5).

F-1 Food Assistance Program State Summary, August 2013

The Food Assistance Monthly Participation Report is a monthly summary of Food Assistance program participation, statewide and for each Iowa county. Breakouts are reported for participants also in the FIP program, those only receiving Food Assistance, and those that are receiving economic assistance under other programs (primarily Medicaid). This report may also be known as the F-1 Report.

A-1 - Monthly Public Assistance Statistical Report Family Investment Program, August 2013

A-1 - Monthly Public Assistance Statistical Report Family Investment Program

City of Oakville public assistance grants independent auditor’s reports, schedule of expenditures of federal awards, schedule of findings and questioned costs, year ended june 30, 2009.

Audit report on the City of Oakville, Iowa for the year ended June 30, 2009.

Educational Leave/Assistance Report FY 2013

Iowa Code section 70A.25(3)(b) states the department shall report the direct and indirect costs of educational leave and educational assistance granted to its employees during the preceding fiscal year. The report shall include the number of employees granted educational leave and the amount of tuition reimbursement allowed; the number of employees granted leave from work to attend classes and who continued to receive their salary and the number of hours of work which those employees were excused; and the number of employees granted a temporary leave of absence from work to attend the classes without pay and the amount of time missed.

A-1 - Monthly Public Assistance Statistical Report Family Investment Program, September 2013

A-1 - Monthly Public Assistance Statistical Report Family Investment Program

F-1 Food Assistance Program State Summary, September 2013

The Food Assistance Monthly Participation Report is a monthly summary of Food Assistance program participation, statewide and for each Iowa county. Breakouts are reported for participants also in the FIP program, those only receiving Food Assistance, and those that are receiving economic assistance under other programs (primarily Medicaid). This report may also be known as the F-1 Report.

A-1 - Monthly Public Assistance Statistical Report Family Investment Program, October 2013

A-1 - Monthly Public Assistance Statistical Report Family Investment Program

F-1 Food Assistance Program State Summary, October 2013

The Food Assistance Monthly Participation Report is a monthly summary of Food Assistance program participation, statewide and for each Iowa county. Breakouts are reported for participants also in the FIP program, those only receiving Food Assistance, and those that are receiving economic assistance under other programs (primarily Medicaid). This report may also be known as the F-1 Report.

F-1 Food Assistance Program State Summary, November 2013

The Food Assistance Monthly Participation Report is a monthly summary of Food Assistance program participation, statewide and for each Iowa county. Breakouts are reported for participants also in the FIP program, those only receiving Food Assistance, and those that are receiving economic assistance under other programs (primarily Medicaid). This report may also be known as the F-1 Report.

A-1 - Monthly Public Assistance Statistical Report Family Investment Program, November 2013

A-1 - Monthly Public Assistance Statistical Report Family Investment Program

Examination of the Iowa Medical Assistance Disproportionate Share Hospital Payments Program and the accompanying schedule identified as Schedule 1 for the Iowa Department of Human Services for the year ended June 30, 2010

Examination of the Iowa Medical Assistance Disproportionate Share Hospital Payments Program and the accompanying schedule identified as Schedule 1 for the Iowa Department of Human Services for the year ended June 30, 2010

Bridging basic science and clinical research - The EASL Monothematic Conference on Translational Research in Viral Hepatitis.

The EASL Monothematic Conference on Translational Research in Viral Hepatitis brought together a group of leading scientists and clinicians working on both, basic and clinical aspects of viral hepatitis, thereby building bridges from bench to bedside. This report recapitulates the presentations and discussions at the conference held in Lyon, France on November 29-30, 2013. In recent years, great advances have been made in the field of viral hepatitis, particularly in hepatitis C virus (HCV) infection. The identification of IL28B genetic polymorphisms as a major determinant for spontaneous and treatment-induced HCV clearance was a seminal discovery. Currently, hepatologists are at the doorstep of even greater advances, with the advent of a wealth of directly acting antivirals (DAAs) against HCV. Indeed, promising results have accumulated over the last months and few years, showing sustained virological response (SVR) rates of up to 100% with interferon-free DAA combination therapies. Thus, less than 25years after its identification, HCV infection may soon be curable in the vast majority of patients, highlighting the great success of HCV research over the last decades. However, viral hepatitis and its clinical complications such as liver cirrhosis and hepatocellular carcinoma (HCC) remain major global challenges. New therapeutic strategies to tackle hepatitis B virus (HBV) and hepatitis D virus (HDV) infection are needed, as current therapies have undeniable limitations. Nucleoside/nucleotide analogues (NUC) can efficiently control HBV replication and reduce or even reverse liver damage. However, these drugs have to be given for indefinite periods in most patients to maintain virological and biochemical responses. Although sustained responses off treatment can be achieved by treatment with (pegylated) interferon-α, only about 10-30% of patients effectively resolve chronic hepatitis B. It was the goal of this conference to review the progress made over the last years in chronic viral hepatitis research and to identify key questions that need to be addressed in order to close the gap between basic and clinical research and to develop novel preventive and treatment approaches for this most common cause of liver cirrhosis and HCC.